Interleukin 2 inducible T cell kinase inhibitor 1 - Corvus Pharmaceuticals
Alternative Names: Interleukin-2-inducible T cell kinase inhibitor 1 - Corvus Pharmaceuticals; ITKi#1Latest Information Update: 29 Apr 2024
At a glance
- Originator Corvus Pharmaceuticals
- Class
- Mechanism of Action Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 27 Mar 2024 Preclinical trials in Immunological disorders in USA (unspecified route)